美康生物
(300439)
| 流通市值：29.32亿 | | | 总市值：38.55亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,135,669,290.81 | 736,221,523.12 | 374,030,860.65 | 1,742,424,499.51 |
| 营业收入 | 1,135,669,290.81 | 736,221,523.12 | 374,030,860.65 | 1,742,424,499.51 |
| 二、营业总成本 | 1,105,821,644.63 | 706,593,829.78 | 350,212,593.71 | 1,525,930,374.42 |
| 营业成本 | 685,534,462.38 | 435,849,307.36 | 225,347,929.5 | 966,144,069.16 |
| 税金及附加 | 13,983,514.19 | 9,213,656.6 | 4,145,273.19 | 15,282,849.54 |
| 销售费用 | 171,847,447 | 104,496,129.65 | 52,108,293.45 | 237,206,923.84 |
| 管理费用 | 133,212,873.01 | 86,924,656.62 | 33,660,531.64 | 165,900,996.86 |
| 研发费用 | 103,113,005.51 | 71,451,238.98 | 35,830,195.42 | 146,467,706.46 |
| 财务费用 | -1,869,657.46 | -1,341,159.43 | -879,629.49 | -5,072,171.44 |
| 其中:利息费用 | 1,147,601.83 | 108,446.4 | 377,141.43 | 2,523,612.15 |
| 其中:利息收入 | 2,996,194.74 | 2,261,671.46 | 1,337,828.91 | 10,351,098.81 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 899,739.61 | 226,892.6 | 605,752.74 | 81,517.67 |
| 加:投资收益 | 2,372,271.46 | 2,342,205.59 | -2,738,528.61 | 14,458,479.33 |
| 资产处置收益 | 13,265.65 | 2,981.27 | 10,588.74 | -665,892.86 |
| 资产减值损失(新) | -2,534,106.76 | -2,404,571.43 | -431,720.71 | -17,776,445.45 |
| 信用减值损失(新) | -7,927,839.64 | -1,303,489.6 | 1,573,699.02 | 20,768,222.16 |
| 其他收益 | 31,430,676.94 | 26,110,145.41 | 11,172,090.16 | 34,170,313.99 |
| 四、营业利润 | 54,101,653.44 | 54,601,857.18 | 34,010,148.28 | 267,530,319.93 |
| 加:营业外收入 | 798,680.4 | 3,334,903.38 | 8,137.54 | 21,893,787.72 |
| 减:营业外支出 | 1,493,753.83 | 992,787.6 | 954,470.67 | 7,064,112.18 |
| 五、利润总额 | 53,406,580.01 | 56,943,972.96 | 33,063,815.15 | 282,359,995.47 |
| 减:所得税费用 | -5,486,989.04 | 1,335,896.63 | 3,284,761.12 | 19,685,270.75 |
| 六、净利润 | 58,893,569.05 | 55,608,076.33 | 29,779,054.03 | 262,674,724.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 58,893,569.05 | 55,608,076.33 | 29,779,054.03 | 262,674,724.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 60,533,779.47 | 56,833,722.63 | 30,397,722.74 | 257,997,230.71 |
| 少数股东损益 | -1,640,210.42 | -1,225,646.3 | -618,668.71 | 4,677,494.01 |
| 扣除非经常损益后的净利润 | 31,206,714.01 | 30,024,575.42 | 20,647,887.87 | 220,406,109.61 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.15 | 0.08 | 0.67 |
| (二)稀释每股收益 | 0.16 | 0.15 | 0.08 | 0.67 |
| 八、其他综合收益 | 1,261,533.54 | 1,302,862.97 | -1,157,261.16 | 10,988,800.8 |
| 归属于母公司股东的其他综合收益 | 1,037,302.33 | 1,063,056.7 | -890,345.17 | 12,198,718.21 |
| 九、综合收益总额 | 60,155,102.59 | 56,910,939.3 | 28,621,792.87 | 273,663,525.52 |
| 归属于母公司股东的综合收益总额 | 61,571,081.8 | 57,896,779.33 | 29,507,377.57 | 270,195,948.92 |
| 归属于少数股东的综合收益总额 | -1,415,979.21 | -985,840.03 | -885,584.7 | 3,467,576.6 |
| 公告日期 | 2025-10-29 | 2025-08-29 | 2025-04-26 | 2025-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |